ERBB2 and neoplasm: Both immuno-PET with [89Zr]trastuzumab and SNIPR PET with [18F]FHBG demonstrated statistically significant increased radiotracer enrichment in HER2+ tumor compared with HER2– tumor (9.9-fold, with P < 0.001, and 9.3-fold, with P = 0.002, respectively) (Fig. 3B).